Although the involvement of factor XI (FXI) and subsequent thrombin activation in the development of angiotensin II-induced vascular inflammation has recently been proposed [11], it is not clear whether thrombin inhibition results in the modulation of NO- and 20-HETE–dependent pathways and whether dabigatran affect Ang II-induced hypertension and endothelial dysfunction. The gene discussed is AGT; the disease is endothelial dysfunction.